| Vol. 11.29 – 7 August, 2020 |
| |
|
|
| The authors investigated whether δ-tocotrienol (δ-TT) might exert its activity by impairing mitochondrial functions. They demonstrated that, in PC3 and DU145 cells, δ-TT impaired mitochondrial respiration and structural dynamics. [Free Radical Biology and Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists determined the effects of grape antioxidants quercetin and/or resveratrol against prostate cancer in the transgenic adenocarcinoma of mouse prostate (TRAMP)-model in prevention and intervention settings. [Cancers] |
|
|
|
| Researchers evaluated the antitumor effect of a next‐generation analog of ralaniten as a monotherapy or in combination with enzalutamide in prostate cancer cells that express AR‐V7 that were resistant to enzalutamide. [Molecular Oncology] |
|
|
|
| Scientists developed curcumin nanoparticles and evaluated their cytotoxicity in docetaxel (DTX)-resistant castration-resistant prostate cancer (CRPC) cells for the treatment of DTX-resistant CRPC. [Biomedicines] |
|
|
|
| In vitro studies showed that low-dose bisphenol A promoted the proliferation of human prostate fibroblasts and epithelial cells, and significantly upregulated the expression of cyclooxygenase-2 (COX-2) and lipocalin-type prostaglandin D synthase (L-PGDS) in the cells. [Scientific Reports] |
|
|
|
| Researchers confirmed autophagy induction by withaferin A (WA) treatment by transmission electron microscopy using three prostate cancer cell lines. Fourteen common genes altered by 8‐ and 16‐hour exposure to WA were identified from human autophagy PCR array and these results were consistent with the RNA‐seq data. [Molecular Carcinogenesis] |
|
|
|
| Investigators integrated a computational proteochemometric systems network pharmacology platform, DrugGenEx‐Net, with primary, continuous cultures of conditionally reprogrammed normal and prostate cancer (PCa) cells derived from treatment‐naive patients with primary PCa. [Prostate] |
|
|
|
| Scientists hypothesized that designed peptides with a wide spectrum of selective antimicrobial activity would also have anticancer activity, and tested this hypothesis with newly designed peptides. [Molecules] |
|
|
|
| The addition of chelerythrine significantly inhibited the proliferation of androgen-independent prostate cancer DU145 and PC-3 cells at the concentration of 5 and 10 μM, but not on androgen-dependent prostate cancer LNCaP cells as well as normal prostate epithelial cell line PrEC cells. [Molecular and Cellular Biochemistry] |
|
|
|
|
| Researchers review the current status of immunotherapy, including new discoveries and precision approaches to prostate cancer, and discuss future directions in the continuously evolving landscape of immunotherapy. [International Journal of Molecular Sciences] |
|
|
|
|
| Cancer Targeted Technology (CTT) announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research Phase IIB grant. [Cancer Targeted Technology (Business Wire, Inc.)] |
|
|
|
| ORIC Pharmaceuticals, Inc. announced it has entered into an exclusive worldwide license agreement with Mirati Therapeutics, Inc. ORIC will have exclusive worldwide rights for the development activities and commercialization of a small molecule allosteric inhibitor program directed towards the polycomb repressive complex 2, a validated oncogenic target across several cancers with promising therapeutic potential in prostate cancer, among other indications. [ORIC Pharmaceuticals, Inc.] |
|
|
|
|
| May 18 – May 21, 2021 Hannover, Germany |
|
|
|
|
|
| Rutgers Cancer Institute of New Jersey – Rutgers, New Jersey, United States |
|
|
|
| European Molecular Biology Laboratory – Hinxton, Cambridge, United Kingdom |
|
|
|
| University of Maryland, Baltimore – Baltimore, Maryland, United States |
|
|
|
| West Virginia University – Morgantown, West Virginia, United States |
|
|
|
| Stanford Institute for Stem Cell Biology and Regenerative Medicine – Stanford, California, United States |
|
|
|
|